The Drug Infusion System Market is expected to reach USD 11.97 Billion by 2030 at 7.20% CAGR during the forecast period 2022-2030. The drug infusion systems are medical devices that allow infusion of drugs like antibiotics, chemotherapy drugs, insulin, painkillers and others in a controlled manner.
The increase in the prevalence of chronic diseases like cardiovascular disease, stroke, cancer, type 2 diabetes, obesity, and arthritis drives the market growth. According to the World Health Organization 2018, 70% of deaths occur due to non-communicable diseases like diabetes, heart disease, stroke, chronic lung disease and heart disease, stroke, cancer worldwide. Also, the rising geriatric population, adoption of technologically advanced devices and rising healthcare spending provide favorable backgrounds for the market to grow. Also, due to their easy to use, portability, ergonomic design, and visual monitoring features favor the potential growth of the market.
However, factors such as the high cost of drug infusion system, shortage of skilled labor and stringent government rules and regulations for product approval are expected to restrict the market growth during the forecast period.
Medical devices called drug infusion systems are used to give patients nourishment and medications such as antibiotics, painkillers, hormones, and chemotherapy treatments. These systems come in a variety of designs, including stationary and ambulatory. The increased incidence of chronic diseases, including cancer, diabetes, and others, along with an aging population and technological breakthroughs in product development, among other factors, primarily drive-up demand for medication infusion systems. The chronic diseases and cancers mentioned above are a few examples of those spreading quickly worldwide. People are frequently affected by chronic diseases for their lives, necessitating protracted therapeutic efforts. Drug infusion systems are applied to that end.
Additionally, the market is well-positioned to expand due to the growing elderly population, the adoption of technologically improved equipment, and rising healthcare costs. Additionally, the market's prospective growth is aided by their characteristics for visual monitoring, portability, ergonomic design, and ease of use. However, throughout the projected period, the market's expansion is predicted to be constrained by the high cost of drug infusion systems, a lack of skilled professionals, and rigorous government regulations. However, throughout the projected period, the market's expansion is predicted to be constrained by the high cost of drug infusion systems, a lack of skilled professionals, and rigorous government regulations. Due to their widespread use in dispensing fluids and medications into patients' bodies, sophisticated infusion systems are used more frequently. Subcutaneous, intravenous, and epidural or enteral are the typical ways that fluids are administered with the aid of an infusion system. With sophisticated infusion devices, the flow of medications may be controlled and monitored. The desire for advanced infusion systems is steadily rising due to the high death rates linked to alternative medication administration techniques.
News:After the US FDA approved reintroducing the medication infusion system, Becton Dickinson stock reached a record high. The business anticipates starting to ship the devices and earning earnings in its fiscal year 2024. For the remainder of the fiscal year 2023, which ends on September 30, it stated that it does not anticipate the Alaris infusion system to provide any appreciable additional revenue.
Research Methodology
Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.
Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.
Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the drug infusion system market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.
Segmentation
The Drug infusion system market is segmented on the basis of product type, mode of administration, application, and end-user. The drug infusion system market, by product type, is sub-segmented into elastomeric infusion system, disposable infusion system, syringe infusion system, peristaltic pump, multi-channel pump, Patient-Controlled Analgesia (PCA) pump, insulin pump, and implantable infusion system. On the basis of application, the market is categorized into oncology/chemotherapy, diabetes, analgesia, nutrition, hematology, pediatrics, and others. The mode of administration is further sub-segmented into intravenous, subcutaneous, arterial, epidural, and others. On the basis of end-user, the market is segmented into hospitals, ambulatory surgical centers, diagnostic centers, and others.
News:The FDA 510(k) clearance request for Koru Medical Systems' Freedom60 infusion system was made public. The application uses the Freedom60 infusion system with a prefilled Hizentra 50 mL syringe. Koru signed a development contract with a provider of subcutaneous immunoglobulin treatment (SCIg) earlier this year. With this agreement, the Freedom Infusion System with a SCIg prefilled syringe was to receive regulatory approval. The FDA approved the 50 mL Hizentra prefilled syringe for Koru in April 2023. Hizentra is the most frequently prescribed subcutaneous immunoglobulin, claims the firm. Additionally, it is the first to be offered in prefilled syringes.
On the basis of region, the drug infusion system market is segmented into the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Drug infusion system Market, by Key Players
Regional Market Summary
The drug infusion system market is dominated by North America owing to the rising chronic diseases region. According to the Heart Disease and Stroke Statistics 2018, 836,546 deaths in the US were due to cardiovascular disease. Such a high incidence rate of cardiovascular diseases drives the market growth in this region
It is estimated that Europe stood second in the Drug infusion system market. Increasing prevalence of chronic disease, rising health care expenditure and health care activities are driving the growth of this market in Europe. As per the Organization for Economic Co-operation and Development (OECD) in 2016, 550,000 working‑age people died due to chronic disease in European Union countries. Such a high prevalence of chronic disease is expected to boost the market in this region.
Asia Pacific was projected to be the fastest growing region for the Drug infusion system market.
Drug infusion systems are frequently used for delivering insulin into patient’s body. Growing prevalence of diabetes influences the market in this region. According to the Asian Diabetes Prevention Initiative, 60% of the world’s diabetic population lives in Asia. This propels the growth of the market in this region.
The Middle East and Africa holds the least share in the global Drug infusion system market due to the presence of stringent government policies and poor economies. However, increasing investment by private market players in this region can boost the market growth.
Market Segmentation and Key Market Players
Drug infusion system Market, by Product Type
Drug infusion system Market, by Application
Drug infusion system Market, by Mode of administration
Drug infusion system Market, by End-user
Drug infusion system Market, by Region
Intended Audience
| Report Attribute/Metric | Details |
| Market Size | USD 11.97 Billion |
| CAGR | 7.20% |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Mode of Administration, Application, and End-user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Medtronic, arcomed AG, Braun Melsungen AG, Baxter, Becton Dickinson and Company, Debiotech S.A., Fresenius SE & Co. KGaA, Halyard Health Inc, ICU Medical Inc, IRadimed Corporation, Insulet Corporation, Terumo Corporation, Smiths Group plc, Tandem Diabetes Care, MOOG INC., Others |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | · Rising geriatric population · Adoption of technologically advanced devices · Rising healthcare spending provide favorable backgrounds |
Drug Infusion System Market Highlights:
Frequently Asked Questions (FAQ) :
Drug infusion system market has a high cost of the procedure, strict government rules, lack of product approval, and lack of skilled labor as major deterrents.
The system has segments like disposable infusion system, elastomeric infusion system, multi-channel pump, syringe infusion system, peristaltic pump, insulin pump, Patient-Controlled Analgesia (PCA) pump, and implantable infusion system.
The applications are diabetes, oncology/chemotherapy, nutrition, hematology, analgesia, pediatrics, and others.
The segments are intravenous, subcutaneous, arterial, epidural, and others.
The end users are diagnostic centers, ambulatory surgical centers, hospitals, and others.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
